Highlights
- Radiopharm has executed a deal with ANSTO to secure the supply of Lutetium-177 (Lu-177).
- The company will use the key isotope in combination with its propriety nanobody in a Phase I therapeutic dose escalation trial in patients with non-small cell lung cancer.
- Radiopharm expects to start the Phase I dose escalating clinical trial in the first quarter of 2023.
Australia-based developer of radiopharmaceutical products, Radiopharm Theranostics (ASX:RAD) has taken another important step in its clinical journey towards cancer treatment.
The company has inked an agreement with Australia's Nuclear Science and Technology Organisation (ANSTO) for the supply of Lutetium-177 (Lu-177).
ANSTO is the home of Australia's most significant landmark and national infrastructure for research. The organisation operates OPAL, which is one of the world’s most modern nuclear research reactors.
Lu-177 - Key isotope for Radiopharm’s Phase I therapeutic trial
Radiopharm needs Lu-177, an isotope non-carrier-added lutetium-177, for its trials in Australia.
The isotope is planned to be used in combination with Radiopharm's propriety nanobody in a Phase I therapeutic dose-escalation trial. The clinical trial would focus on patients with non-small cell lung cancer.
Radiopharm plans to commence the trial in Q1 2023 in partnership with GenesisCare and ANSTO.
The agreement will come into effect from 01 December 2022.
Shaun Jenkinson, CEO of ANSTO, said “We are excited that the isotopes we will supply to Radiopharm Theranostics will go toward expanding this vision at it seeks to revolutionise cancer treatment.”
This is what Radiopharm CEO and Managing Director has to say
© 2022 Kalkine Media®, Data and image source: Company update
Inside Radiopharm’s key agreements during 2022
This year, Radiopharm has secured several key agreements for the smooth running of its clinical trials.
© 2022 Kalkine Media®, Data source: Company update
RAD shares were trading at AU$0.120 apiece in the early hours of 23 November 2022.